Related Experiment Video
Updated: Aug 18, 2026

Optical Frequency Domain Imaging of Ex vivo Pulmonary Resection Specimens: Obtaining One to One Image to Histopathology Correlation
Published on: January 22, 2013
A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma
P V Woolley1, C J Schultz, G I Rodriguez
1Laurel Highlands Cancer Program, Conemaugh's Memorial Medical Center, Lee Hospital, Johnstown, PA, USA.
Abstract:
We have conducted a study of ilmofosine (1-hexadecylthio; 2-methoxyethyl-rac-glycero-3-phosphocholine) in non-small cell bronchogenic carcinoma, using a schedule of continuous infusion for 5 days and a dose of 300 mg/m2/day. Toxicities were gastrointestinal (nausea, vomiting, diarrhea), fatigue and liver function abnormalities. These were severe and resulted in the removal of some patients from study. No consistent pattern of bone marrow suppression was seen. No tumor regressions occurred in 14 evaluable patients including 5 with no prior therapy. We conclude that ilmofosine is inactive in this tumor at this dose and schedule.
Related Concept Videos
Treatment Resistant Cancers
Treatment Resistent Cancers
Clinical Trials: Overview
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

